The update was based on data from the phase 3 PSO-LONG trial, a randomized, double-blind, vehicle-controlled study that evaluated the long-term use of Enstilar Foam in 545 adults. The Food and Drug ...

NMPA approval of Enstilar® in China marks a significant milestone for LEO Pharma, expanding access to a new treatment option ...

THORNHILL, ON, Dec. 3, 2018 /CNW/ - LEO Pharma Canada has announced that as of December 1 st, 2018, Enstilar ® has been added as a Regular Benefit through the Alberta Drug Benefit List. Enstilar ® ...

The FDA has approved Leo Pharma’s Enstilar foam for the treatment of plaque psoriasis. The approval comes on the back of a clinical trial that showed patients achieved significant degrees of ...

Please provide your email address to receive an email when new articles are posted on . LEO Pharma announced in a press release that Enstilar has been approved by the FDA for the topical treatment of ...

Please provide your email address to receive an email when new articles are posted on . The long-term, vehicle-controlled, double-blind, phase 3 PSO-LONG trial compared twice-weekly Enstilar foam ...

LEO Pharma A/S today announced that new data being presented at the 23 rd World Congress of Dermatology shows aerosol foam Enstilar ® (calcipotriol/betamethasone ...

A simple-to-use spray-on foam that quickly vanishes into the skin is the latest weapon in the battle against the debilitating skin condition psoriasis. Clinical trials into the newly licensed ...

A FOAM spray has been launched to help treat people with plaque psoriasis, a chronic, inflammatory skin condition which affects thousands of people in the UK. LEO Pharma has launched Enstilar, billing ...

FOR DISTRIBUTION TO UK CONSUMER MEDIA ONLY (EXCLUDING REPUBLIC OF IRELAND AND MEDICAL MEDIA) Adherence is a significant challenge for patients living with psoriasis (studies consistently suggest that ...

Licence marks first combination foam spray for plaque psoriasis: Enstilar ® (calcipotriol/betamethasone dipropionate) 50 micrograms/g + 0.5mg/g cutaneous foam LEO ...

LEO Pharma, an independent, research-based pharmaceutical company, announced that the US Food and Drug Administration (FDA) has approved Enstilar (calcipotriol ...